Effect of bosentan therapy in persistent pulmonary hypertension of the newborn

• Κύριοι συγγραφείς: Gunlawadee Maneenil (Συγγραφέας), Anucha Thatrimontrichai (Συγγραφέας), Waricha Janjindamai (Συγγραφέας), Supaporn Dissaneevate (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Elsevier, 2018-02-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Background: Persistent pulmonary hypertension of the newborn (PPHN) contributes to neonatal hypoxemia and is associated with a high mortality. Some PPHN patients are unresponsive to inhaled nitric oxide (iNO). Bosentan, an oral endothelin-1 receptor antagonist, reduces pulmonary vascular resistance...